



April 7, 2026

Dear Rett Community,

We are excited to share that DAYBUE® STIX (trofinetide) for oral solution, a dye- and preservative-free powder formulation, is now broadly available in the United States for the treatment of Rett syndrome in adults and pediatric patients two years of age and older. The new formulation, approved by the U.S. Food and Drug Administration (FDA) in December 2025, is bioequivalent to the original DAYBUE® oral solution, delivering the same efficacy and safety profile.

Informed by the invaluable feedback we received from patients, caregivers, and healthcare providers, DAYBUE STIX was developed to offer new flexibility and choice regarding the dose volume and taste of their DAYBUE treatment.

The efficacy and safety of DAYBUE STIX is based on the results of the pivotal Phase 3 LAVENDER™ study with DAYBUE oral solution in patients with Rett syndrome. The approval of this new formulation was informed by the results of a bioequivalence study, which demonstrated that both original DAYBUE oral solution and the new DAYBUE STIX for oral solution powder formulation provide comparable exposure.

We continue to be thankful for the Rett syndrome community and their support as we make this new formulation available to the families across the U.S. At Acadia we are committed to providing the best possible experience for patients and their families who want to try DAYBUE STIX. Please discuss your treatment options with your healthcare provider or treating physician.

All our best,
The Acadia Rett team